Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines

被引:97
作者
Solomon, Diane [1 ]
Breen, Nancy
McNeel, Timothy
机构
[1] NCI, Div Canc Prevent, Rockville, MD USA
[2] Natl Canc Inst, Div Canc Control & Populat Sci, Rockville, MD USA
[3] Informat Management Serv Inc, Silver Spring, MD USA
关键词
D O I
10.3322/canjclin.57.2.105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The remarkable success achieved in cervical cancer prevention is largely attributable to cervical cytology screening, also known as the Papanicolaou (Pap) test. The American Cancer Society (ACS) revised screening guidelines for Pap testing in 2002. The impact of these changes on future numbers of Pap tests has not been assessed. Using National Health Interview Survey (NHIS) data to determine historical screening patterns, we extrapolate the numbers of Pap tests that would be performed through 2010, under 5 different scenarios of implementation of screening guidelines. From 1993 to 2003, there was a steady increase in the number of Pap tests, with an estimated 65.6 million Pap tests performed in 2003. Approximately two thirds of women born after 1930 reported having been screened within the previous year, and 85% within the previous 3 Fifteen percent of Pap tests were performed in hysterectomized women, most of whom, according to current guidelines, should be screened. Based on population projections, if screening behavior remains unchanged, 75 million Pap tests will be 2010. Full compliance with ACS guidelines would approximately halve the total number of tests to 34 million. Potentially, with appropriate allocation of resources according to guidelines, all women could be screened and the total number of Pap tests despite projected increases in the population.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 21 条
[1]  
ACOG Comm Obstet Practice, 2003, OBSTET GYNECOL, V102, P415
[2]  
[Anonymous], 2000, Vital Health Stat 2, P1
[3]  
[Anonymous], US INT PROJ AG SEX R
[4]  
*CDCP, ACIP PROV REC US QUA
[5]  
*CDCP ACIP, 2006, MMWR-MORBID MORTAL W, V5, pQ1
[6]   Hysterectomy rates in the United States 1990-1997 [J].
Farquhar, CM ;
Steiner, CA .
OBSTETRICS AND GYNECOLOGY, 2002, 99 (02) :229-234
[7]   Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more [J].
Goldie, SJ ;
Kim, JJ ;
Wright, TC .
OBSTETRICS AND GYNECOLOGY, 2004, 103 (04) :619-631
[8]   Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, C ;
Ferris, DG ;
Jenkins, D ;
Schuind, A ;
Zahaf, T ;
Innis, B ;
Naud, P ;
De Carvalho, NS ;
Roteli-Martins, CM ;
Teixeira, J ;
Blatter, MM ;
Korn, AP ;
Quint, W ;
Dubin, G .
LANCET, 2004, 364 (9447) :1757-1765
[9]  
HILDESHEIM A, 2006, 23 INT PAP C CLIN WO
[10]   Cancer statistics, 1999 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1999, 49 (01) :8-31